Literature DB >> 24142575

Prognostic impact of p300 expression in patients with colorectal cancer.

Jung Wook Huh1, Hee Cheol Kim, Seok Hyung Kim, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun.   

Abstract

BACKGROUND: This study evaluated the expression of p300 in colorectal cancer, its relationship with clinicopathological characteristics, and its potential prognostic significance.
METHODS: The expression of p300 was measured using immunohistochemistry in tumors and surrounding normal mucosa from 199 patients with primary colorectal cancer. The patients were followed for a median period of 83 months.
RESULTS: Nuclear p300 expression was significantly associated with histology (P = 0.031) and lymph node involvement (P = 0.019). When the low and high p300 groups were subdivided according to tumor location, the disease-free survival rate differed only for the patients with colon cancer (P = 0.008). In addition, the disease-free survival significantly differed with p300 expression for stage II disease (P = 0.038), but not for stage III disease. Multivariate analysis revealed that lymph node involvement (P = 0.014) and p300 expression (P = 0.032) were independent predictors of overall survival in adenocarcinomas.
CONCLUSION: The overexpression of p300 may be an independent favorable prognostic factor for disease-free survival in patients with colorectal cancer.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  colorectal cancer; immunohistochemistry; p300

Mesh:

Substances:

Year:  2013        PMID: 24142575     DOI: 10.1002/jso.23405

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

2.  Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta-analysis.

Authors:  Zihan Liu; Yonglai He; Xiaojuan Lian; Hong Zou; Yalan Huang; Ning Wang; Jianming Hu; Xiaobin Cui; Jin Zhao; Wenjie Zhang; Wenyi Gu; Lijuan Pang; Yan Qi
Journal:  Exp Ther Med       Date:  2019-08-16       Impact factor: 2.447

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 4.  CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.

Authors:  Michael Bordonaro; Darina L Lazarova
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

5.  Histone H3 lysine 27 acetylation is altered in colon cancer.

Authors:  Jakub Karczmarski; Tymon Rubel; Agnieszka Paziewska; Michal Mikula; Mateusz Bujko; Paulina Kober; Michal Dadlez; Jerzy Ostrowski
Journal:  Clin Proteomics       Date:  2014-06-03       Impact factor: 3.988

Review 6.  Expression and role of nuclear receptor coregulators in colorectal cancer.

Authors:  Mouna Triki; Marion Lapierre; Vincent Cavailles; Raja Mokdad-Gargouri
Journal:  World J Gastroenterol       Date:  2017-07-07       Impact factor: 5.742

7.  Subcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma.

Authors:  Xiaowei Li; Keying Che; Liguang Wang; Tiehong Zhang; Guanghui Wang; Zhaofei Pang; Hongchang Shen; Jiajun Du
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

8.  The prognostic capacities of CBP and p300 in locally advanced rectal cancer.

Authors:  Felix Rühlmann; Indra Maria Windhof-Jaidhauser; Cornelius Menze; Tim Beißbarth; Hanibal Bohnenberger; Michael Ghadimi; Sebastian Dango
Journal:  World J Surg Oncol       Date:  2019-12-19       Impact factor: 2.754

9.  The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma.

Authors:  Juan Pablo Rigalli; Matthias Reichel; Tasmin Reuter; Guillermo Nicolás Tocchetti; Gerhard Dyckhoff; Christel Herold-Mende; Dirk Theile; Johanna Weiss
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

10.  p300 Knockout Promotes Butyrate Resistance.

Authors:  Darina L Lazarova; Michael Bordonaro
Journal:  J Cancer       Date:  2017-09-20       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.